Docetaxel and cisplatin plus fluorouracil compared with modified docetaxel, cisplatin, and 5-fluorouracil as first-line therapy for advanced gastric cancer: A retrospective analysis of single institution

Neoplasma

Volumn 59, Issue 2, 2012, Pages 233-236

  Inal, A ^a   Kaplan, M A ^a   Kucukoner, M ^a   Isikdogan, A ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

Advanced gastric cancer; Cisplatin; Docetaxel; Fluorouracil

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA; ADENOCARCINOMA; CLINICAL TRIAL; COLLOID CARCINOMA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SIGNET RING CARCINOMA; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SIGNET RING CELL; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861540507     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_030     Document Type: Article

References (13)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E et al. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. http://dx.doi.org/10.3322/caac.20107
2. KAMANGAR F, DORES GM, ANDERSON WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JCO 2006; 24: 2137-50. http://dx.doi.org/10.1200/JCO.2005.05.2308
3. ROTH AD, FAZİO N, STUPP R, FALK S, BERNHARD J et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007; 25: 3217-3223. http://dx.doi.org/10.1200/JCO.2006.08.0135
4. VAN CUTSEM E, MOİSEYENKO VM, TJULANDİN SA, MAJLİS A, CONSTENLA M et al. V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006; 24: 4991-4997. http://dx.doi.org/10.1200/JCO.2006.06.8429
5. FAHLKE J, RİDWELSKİ K, SCHMİDT C, HRİBASCHEK K, STUEBS P ET AL. et al. A multicentre phase II study of docetaxel plus cisplatin for the treatment of advanced gastric cancer. Chemotherapy 2007; 53: 454-460. http://dx.doi.org/10.
6. KİM KH, JEUNG KJ, KİM HJ, BAE SB, KİM CK et al. Phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with recurrent or metastatic gastric cancer. Cancer Res Treat 2007; 39: 49-53. http://dx.doi.org/10.4143/crt.2007.39.2.49
7. AJANİ JA, FODOR MB, TJULANDİN SA, MOİSEYENKO VM, CHAO Y et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23: 5660-5667. http://dx.doi. org/10.1200/JCO.2005.17.376
8. MURAD AM, SANTİAGO FF, PETROİANU A, ROCHA PR, RODRİGUES MA et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. http://dx.doi.org/10.1002/1097-0142(19930701)72:1<37::AIDCNCR2820720109> 3.0.CO;2-P
9. MURAD AM, SANTİAGO FF, PETROİANU A, ROCHA PR, RODRİGUES MA et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41. http://dx.doi.org/10.1038/bjc.1995.114
10. PYRHONEN S, KUİTUNEN T, NYANDOTO P, KOURİ M. Randomized comparison of fluorouracil epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587-91. http://dx.doi.org/10.1023/A:1008243606668
11. WAGNER AD, GROTHE W, HAERTİNG J, KLEBER G, GROTHEY A et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. JCO 2006; 24: 2903-9
12. OZDEMİR NY, ABALİ H, OKSÜZOǦLU B, BUDAKOGLU B, UNCU D et al. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol (2010) 27: 680-684. http://dx.doi.org/10.1007/s12032-009-9268-y
13. KOS FT, UNCU D, OZDEMİR N, BUDAKOGLU B, ODABAŞ H et al. Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer. Chemotherapy 2011; 57: 230-235. http://dx.doi.org/10.1159/000327840